<code id='44DA2841A1'></code><style id='44DA2841A1'></style>
    • <acronym id='44DA2841A1'></acronym>
      <center id='44DA2841A1'><center id='44DA2841A1'><tfoot id='44DA2841A1'></tfoot></center><abbr id='44DA2841A1'><dir id='44DA2841A1'><tfoot id='44DA2841A1'></tfoot><noframes id='44DA2841A1'>

    • <optgroup id='44DA2841A1'><strike id='44DA2841A1'><sup id='44DA2841A1'></sup></strike><code id='44DA2841A1'></code></optgroup>
        1. <b id='44DA2841A1'><label id='44DA2841A1'><select id='44DA2841A1'><dt id='44DA2841A1'><span id='44DA2841A1'></span></dt></select></label></b><u id='44DA2841A1'></u>
          <i id='44DA2841A1'><strike id='44DA2841A1'><tt id='44DA2841A1'><pre id='44DA2841A1'></pre></tt></strike></i>

          explore

          explore

          author:comprehensive    Page View:9575
          Cambridge: Biogen
          Ruby Wallau for STAT

          A plan to use new genetic techniques to treat non-genetic forms of ALS failed in an early study, Ionis and Biogen announced Thursday. The companies said they would discontinue the program.

          In the randomized, 99-person trial, the companies tested a drug designed to silence a gene called ATXN2. Over the last decade, numerous drugs have been built to silence genes in ALS patients, but most of them have, fittingly, focused on rare genetic forms of ALS, where neurons die largely because of the work of a single mutated stretch of DNA.

          advertisement

          This approach has led to an approved drug for one very small subset of ALS cases, driven by the gene SOD1, and drugs for other genes are in trials. But only perhaps 10% — or at most 20% — of ALS cases are genetic. The hope, based on some genetic data and promising mice experiments, was that lowering ATXN2 would help any patient who develops ALS.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Medical records are filled with copy
          Medical records are filled with copy

          AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

          read more
          Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources
          Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

          3:14InthisMarch4,2023,filephoto,formerPresidentDonaldTrumpspeakstoreportersbeforeatGaylordNationalRe

          read more
          Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
          Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

          AdobeSometimes,anappleadayreallyisjustwhatthedoctorordered.Andforthepastseveralyears,organizationsli

          read more

          At ASCO, AstraZeneca reports strong data for breast cancer drug

          ThefuturelooksevenbrighterfortheblockbusterEnhertu,showcasedhereatASCO.ADAMFEUERSTEIN/STATCHICAGO—Th